China Immunotech   Report issue

For profit Phase 1 Phase 2
Founded: Beijing China (2018)

Organization Overview

First Clinical Trial
2018
NCT03648697
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

China Immunotech (Beijing) Biotechnology Co., Ltd. | China Immunotech Co., Ltd. | China Immunotech Pharmaceuticals Co.Ltd.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 1)

Carcinoma, Hepatocellular (Phase 1)

Communicable Diseases (Phase 1)

Cytomegalovirus Infections (Phase 1)

Infections (Phase 1)

Leukemia (Phase 1)

Leukemia, B-Cell (Phase 1)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)

Lymphoma (Phase 1)

Lymphoma, B-Cell (Phase 1)

Nasopharyngeal Carcinoma (Phase 2)

Neoplasms (Phase 1)

Virus Diseases (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 11
  • # of Trial APIs: 8